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Abstract 
ŵĂũŽƌŚĂůůŵĂƌŬŽĨůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ ? ?ŝƐƚŚĞĨŽƌŵĂƚŝŽŶŽĨƚŽǆŝĐĂŐŐƌĞŐĂƚĞƐĐŽŵƉŽƐĞĚŽĨƚŚĞ
E-amyloid peptide (AE). Given that AE peptides are known to co-localize within mitochondria and 
interact with 17E-HSD10, a mitochondrial protein expressed at high levels in AD brains, we have 
investigated the inhibitory potential of 17E-HSD10 against AE aggregation across a range of 
physiological conditions. The fluorescence self-quenching (FSQ) of AE(1-42), labelled with HiLyte 
Fluor 555, was used as a sensing strategy to evaluate the inhibitory effect of 17E-HSD10 under well-
established conditions to grow distinct AE morphologies. Our results indicate that 17E-HSD10 
preferentially inhibits the formation of globular and fibrillar-like structures but has no effect on the 
growth of amorphous plaque-like aggregates at endosomal pH 6. This work provides insights into the 
dependence of the AE-17E-HSD10 interaction with the morphology of AE aggregates and how this 
impacts enzymatic function. 
 
<ĞǇǁŽƌĚƐ ?E-ŵǇůŽŝĚ ƉĞƉƚŝĚĞ ? ? ?E-ŚǇĚƌŽǆǇƐƚĞƌŽŝĚ ĚĞŚǇĚƌŽŐĞŶĂƐĞ ƚǇƉĞ  ? ? ? ůǌŚĞŝŵĞƌ ?Ɛ ĚŝƐĞĂ Ğ ?
ĨůƵŽƌĞƐĐĞŶĐĞƐĞůĨ-ƋƵĞŶĐŚŝŶŐ ?ŶĞƵƌŽĐŚĞŵŝƐƚƌǇ 
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Abbreviations 
17E-HSD10 = 17E-hydroxysteroid dehydrogenase type 10  
ABAD  = amyloid-binding alcohol dehydrogenase 
AD  = Alzheimer's disease 
AFM  = atomic force microscopy 
AICD  = amyloid precursor protein intracellular domain 
APP  = amyloid precursor protein 
AE  = amyloid-E peptide 
BACE  = ɴ-secretase 
BBB  = blood Wbrain barrier 
CD  =  circular dichroism 
DLS  = dynamic light scattering 
DMSO  = dimethyl sulfoxide 
EM  = electron microscopy 
ER  = endoplasmic reticulum 
ETC  = electron transport chain 
FSQ  =  Fluorescence self-quenching 
HFIP  = 1, 1, 1, 3, 3, 3- hexafluoro-2-propanol 
Hsp  = heat shock protein 
MES  = 2-(N-morpholino)ethanesulfonic acid  
ROS  = reactive oxygen species 
STD NMR = saturated transfer difference NMR 
SDR  = short chain dehydrogenase reductase 
ThT  = thioflavin T 
TFE  = tetrafluoroethylene 
TIM  = translocase of the inner membrane 
TOM  = translocase of the outer membrane 
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Introduction 
   ůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ ? ?ŝƐƚŚĞŵŽƐƚĐŽŵŵŽŶĨŽƌŵŽĨĚĞŵ ŶƚŝĂ ?ĚĞĨŝŶĞĚĐůŝŶŝĐĂůůǇĂƐĂƉƌŽŐƌĞƐƐŝǀĞ
loss of declarative memory leading to complete social dependence and eventual death. It is 
characterized by cerebral extracellular amyloid plaques and intracellular neurofibrillary tangles.[1] 
The molecular mechanisms governing AD pathogenesis are still not fully understood [2,3] owing to its 
intrinsic complexity and no effective treatment has been developed to date. Nevertheless, it has 
been shown that the polymerization of the E-amyloid peptide (AE) into amyloid fibrils, and other 
morphologies including plaques and oligomeric species, constitutes a hallmark of AD.[4] The 
development of AE inhibitors has thus received much attention, with peptides[5 W7] and small organic 
molecules[8 W10] now established as the two main classes of amyloid inhibitors. AE production, 
aggregation and accumulation within the brain is summarised in Figure 1.  
   Since the discovery that AE peptides are found within the mitochondria of AD brains,[11] several 
attempts have been made to comprehend the mechanisms underpinning AE-induced mitochondrial 
dysfunction,[12 W20] and to identify receptors which may be involved in this process.[21] Specifically, the 
observed interaction between mitochondrial proteins with aggregated AE peptides has been 
suggested as a potential pathogenic mechanism contributing to AE neurotoxicity in AD.[17-22] For 
instance, the 17E-hydroxysteroid dehydrogenase type 10 (17E-HSD10) or also commonly known as 
amyloid-binding alcohol dehydrogenase (ABAD))[21,23 W26] constitutes one of such mitochondrial AE-
interacting proteins.[6,27] 17E-HSD10 is a 27 kDa multifunctional enzyme expressed in all cell types 
and is thought to play a central role in the E-oxidation of fatty acids,[24,28] isoleucine degradation, 
catalysis and oxidation of alcohols and the reduction of aldehydes and ketones.[22] In transgenic 
mouse models for AD and in human AD sufferers, 17E-HSD10 has been shown to have increased 
expression levels and has gained considerable attention as a result of its ability to bind AE, suppress 
AE-induced apoptosis and free-radical generation in neurons.[11] It is known that the interaction 
between 17E-HSD10 and AE(1-40), AE(1-42) and AE(1-20) takes place in the nanomolar range (Kd ~ 
40-80 nM),[11] which agrees well with the low cellular concentrations of AE peptide expected at the 
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early stages of AD. In addition, mutagenesis and inhibition studies have suggested that the LD loop of 
17E-HSD10, comprising residues C91-D119, plays a critical role in AE binding.[11] However, the lack of 
electron density for AE and the LD loop of 17E-HSD10 in the crystal structure of the complex 
precluded the detailed characterization of the binding interface. A recent NMR study suggested that 
the 17E-HSD10/AE interaction takes place mostly via contacts between AE residues 17-20 (LVFF) and 
hydrophobic residues within the LD loop.
[29] Importantly, saturation transfer difference (STD-NMR) 
experiments also suggested that AE and nicotinamide adenine dinucleotide (NAD) binding to 17E-
HSD10 are mutually exclusive, thus providing an explanation regarding how AE-binding may alter the 
activity of 17E-HSD10.[29] The interaction between 17E-HSD10 and AE in vivo has also been further 
demonstrated within mitochondria using co-localization and co-immunoprecipitation techniques,[11] 
but there are still many aspects of this interaction that remain poorly understood. 
   Here, we have employed a fluorescence self-quenching (FSQ) approach to investigate the 
interaction between 17E-HSD10 and amyloid aggregates. FSQ is based on the site-specific 
positioning of a fluorescent dye (HiLyte Fluor 555, Figure S1) at the N-terminal of the AE sequence. 
In FSQ, the fluorescence of the dye is maximal for non-aggregated AE but becomes progressively 
quenched as monomers aggregate, resulting in a combination of partially-quenched and non-
emissive fluorophores (Figure 2) that decrease the overall fluorescence emission as aggregation 
progresses. The advantages of FSQ as an alternative to assays based on the binding of extrinsic dyes 
such as Thioflavin-T (ThT) to AE aggregates have been recently discussed.[29,33-35] There are many 
reasons for this work, firstly we want to determine the applicability of FSQ methods to investigate 
the interaction between amyloid and 17E-HSD10 as it has been previously shown for the interaction 
between AE and the 20 kDa heat shock protein (Hsp20).[33] Secondly, despite evidence for an in vivo 
association of 17E-HSD10 and AE sequences, it is not known whether 17E-HSD10 inhibits equally all 
amyloid morphologies or, in contrast, exhibits a certain degree of selectivity for some types of 
amyloid aggregates. In addition to inhibit amyloid aggregation, it has been shown that 17E-HSD10 in 
complex with AE becomes dysfunctional and its enzymatic inactivation leads to an increase in 
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mitochondrial stress and ultimately loss of neuron viability.[36] However, no in vitro data has been 
reported to confirm this aspect and it is unclear how both consequences of the interaction between 
17E-HSD10 and AE, inhibition of aggregation and enzymatic inactivation of 17E-HSD10, relate to 
each other. 
   Our results using FSQ demonstrate that 17E-HSD10 specifically inhibits the formation of NaCl-
induced fibrils and globular aggregates but has no effect on the formation of plaque-like structures 
grown at conditions mimicking endosomal pH. Furthermore, using an absorbance assay that 
monitors the conversion of NADH into NAD+, we investigated the impact of these morphologies on 
the function of 17E-HSD10. It was found that although the formation of fibrils and globules is 
inhibited to similar levels by 17E-HSD10, their influence on 17E-HSD10 function is significantly 
different, with fibrillary structures showing the highest level of enzymatic inhibition. Lastly, a 
comparison between FSQ and the widely used ThT-based assay revealed that the ThT reporter dye 
exhibits, even in the absence of amyloid, a significant time-dependent fluorescence enhancement 
under the aggregation conditions used to promote the formation of globular amyloid structures. 
Thus, our findings highlight the limitations of ThT-based methods to monitor aggregation across 
different conditions and confirm that FSQ-based assays constitute a superior analytical tool to 
investigate amyloid self-assembly and when searching for small-molecule or protein-based inhibitors 
of this process. 
 
Results  
Monitoring amyloid aggregation and inhibition using fluorescence self-quenching 
   Aggregation of AE(1-42) functionalized at the N-terminal with HiLyte Fluor 555 (AE555) into three 
different morphologies, namely globules, fibrils and plaques, was studied in real-time by 
fluorescence self-quenching (FSQ) at AE555: 17E-HSD10 molar ratios of 1:0 (control), 1:1 and 2:1 as 
described in the Experimental Section. The rationale for choosing these morphologies was two-fold. 
Firstly, they constitute representative examples of the vast array of amyloid morphologies than can 
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be generated as a function of environmental conditions.[43] Secondly, aggregation protocols to 
reproducibly promote the formation of these AE(1-42) aggregates are well-established and the 
resulting aggregates have been extensively characterized using structural imaging methods including 
atomic-force microscopy (AFM) and electron-microscopy (EM).[32 W51] In a previous study we have 
already shown using EM that the presence of the HiLyte Fluor 555 dye at the N-terminus of the 
AE(1-42) peptide (AE555) does not affect the aggregation kinetics or the morphology of the 
aggregates.[34] Indeed, we observed amyloid structures of AE555 with diameters of ~ 4 nm (fibrils) and 
~ 22 nm (globules) which are identical to those obtained in the absence of N-terminal 
functionalization.[32,33,52] At pH 6 and pH 4 we observed the formation of amorphous plaque-
like aggregates, as previously reported under similar acidic conditions.[52] 
  After having clarified the similar structural and kinetic behavior of AE555 compared with unlabelled 
AE(1-42) and before describing our findings in the context of its application to the interaction 
between AE and 17E-HSD10, it is worth to briefly summarize the concept of FSQ-based assays. FSQ 
methods rely on the close positioning of the dyes induced by the tight packing of amyloid chains in 
the aggregated structure that triggers a very efficient quenching mechanism. This self-quenching 
mechanism is responsible for the observed time-dependent decrease in fluorescence emission of the 
HiLyte Fluor 555 dye[34] as the aggregation progresses and depends on the proximity and local 
density of identical dyes in the neighborhood of a given fluorophore (Figure 2). An in-register parallel 
beta-sheet packing placing the N-terminal domains next to each other, has been recently reported 
using solid-state NMR,[43] thus providing a molecular-level explanation of how the organization of the 
amyloid fibrils enables a very efficient self-quenching process. As suggested in that work, 
hydrophobic assembly of two or more of these protofibrils might be possible and this could 
additionally contribute to place the dyes in close proximity.[43] 
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17E-HSD10 inhibits the formation of fibril-like structures 
   The kinetics of amyloid aggregation and the predominant morphologies arising from this process 
are known to be extremely sensitive to environmental conditions including pH, temperature and 
ionic strength.[42,52] For instance, we have previously demonstrated by TEM, FSQ and ThT assays that 
fibrillary structures constitute the predominant morphology at pH 7.9 and moderate concentrations 
of NaCl (150 mM).[33] Here, we used similar conditions to determine the impact of 17E-HSD10 on the 
formation of these amyloid aggregates. In the absence of 17E-HSD10 when a non-aggregated 
solution of 1 PM AE555 was incubated in 50 mM Tris-HCl, 150 mM NaCl buffer (pH 7.9) at 37oC, we 
observed a decrease in the fluorescence intensity of 23.1 ± 1.2 % (Figure 3A). In the case where 1 
PM AE555 was induced to aggregate in the presence of 17E-HSD10 under the same experimental 
conditions, significant levels of inhibition were detected at the two AE555: 17E-HSD10 molar ratios 
investigated. Specifically, the fluorescence intensity was quenched by 7.7 ± 0.5 % when the molar 
ratio was 2:1 (Figure 3B) and decreased to undetectable levels at an AE555: 17E-HSD10 molar ratio of 
1:1 (Figure 3C). 
   In order to validate and compare our FSQ assay against those already available, we used ThT as a 
sensor of amyloid fibril aggregation.[38] ThT (1.5 PM) acting on unlabelled AE(1-42) in 50 mM Tris, 
150 mM NaCl (pH 7.9) buffer undergoes a 60.4 r 0.7 % enhancement of fluorescence emission and 
exhibits a time-dependence for the aggregation process similar to that previously observed using 
FSQ, with both methods reaching a plateau at ~ 50 minutes (Figure 3A). At an AE555: 17E-HSD10 
molar ratio of 2:1, the ThT fluorescence enhancement decreased to a value of 8.1 r 0.2 % (Figure 3B) 
and at 1:1 molar ratio no ThT enhancement was detected (Figure 3C). Thus, in agreement with the 
data obtained using FSQ, the ThT-based assay confirms that 17E-HSD10 interacts with AE(1-42) and 
efficiently inhibits the formation of amyloid fibrils in a concentration-dependent manner. The 
fluorescence spectra of AE555 obtained at the different AE:17E-HSD10 molar ratios used are shown 
in Figure S2 and the quenching rates obtained from the global fit of the aggregation profiles at 1:0 
and 2:1 AE555: 17E-HSD10 molar ratios using FSQ and ThT are summarized in Table S1. 
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   A dependence of the inhibitory effect of 17E-HSD10 with the AE555: 17E-HSD10 molar ratio agrees 
well with the observation that 0.5 µM ĐŽŶĐĞŶƚƌĂƚŝŽŶƐŽĨ ‘in vitro ĂŐĞĚ ?E(1-42) had no effect on the 
dehydrogenase activity of the enzyme, whereas a 10-fold increase in AE(1-42) concentration caused 
substantial inhibition (~ 50 %) of 17E-HSD10 activity.[23] The inhibitory effect observed here for 17E-
HSD10 against fibrillary aggregates is similar to that observed for other proteins with no reported 
chaperone activity such as E-lactoglobulin, D-lactalbumin and lysozyme.[58] These proteins have been 
shown to delay the formation of fibrillar aggregates at 1:1 molar ratios (protein: AE), whereas the 
enzyme catalase and pyruvate kinase completely suppressed amyloid aggregation at a much lower 
molar ratio of 1:100 (protein: AE).[58] Several mechanisms have been proposed to explain the 
inhibitory effect of these proteins at sub-stoichiometric amounts, including the interaction with 
monomeric peptides present in the E-sheet conformation and the formation of complexes with pre-
fibrillar oligomers to slow down or prevent their growth into fibrils. It is unclear at this stage whether 
the inhibitory effect we observed for 17E-HSD10 towards the formation of fibrillar oligomers using 
both FSQ- and ThT-based assays shares similar mechanisms as those acting on non-chaperone 
proteins.  However, the fact that no interaction between 17E-HSD10 and monomeric AE has been 
observed using SPR experiments,[11] and that no binding was observed in the NMR titration of 17E-
HSD10 into amyloid monomers[29] suggests that 17E-HSD10 might act by forming dead-end AE: 17E-
HSD10 aggregates as observed for E-lactoglobulin and catalase using 1H-15N-HSQC NMR 
spectroscopy. 
17E-HSD10 inhibits the formation of rapidly growing globular aggregates 
    The formation of soluble amyloid oligomers and spherical aggregates is known to induce rapid cell 
degeneration, thus suggesting that soluble AE aggregates might have an increased toxicity over 
plaques and AE fibrils.[51] The formation of these globular species is known to be accelerated in the 
presence of lipids and other interfaces; a process that under certain conditions may lead to the 
formation of AE pores that disrupt the cellular membrane.[48] The addition of small amounts of 
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fluorinated solvents such as 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) and 2,2,2-tri-fluoroethanol 
(TFE) as co-solvents to a solution of monomeric AE has been demonstrated as a method to induce 
the formation of amyloid aggregates.[46] For instance, it has been shown that HFIP concentrations A? 4 
% (v/v) induce the formation of globular structures in vitro.[42] HFIP droplets formed at these 
concentrations in an aqueous solution have been hypothesised to act as a growing interface where 
amyloid monomers can nucleate and accelerate growth as observed at the interface of biomimetic 
membranes including ganglioside micelles and lipid-rafts.[48] Moreover, it has been proposed that the 
toxicity of these globular structures may be responsible for the cognitive problems associated to the 
use of polyfluorinated anaesthetic compounds.[55] 
   To investigate the interaction and potential inhibitory properties of 17E-HSD10 under these 
globular forming conditions, we carried out FSQ experiments using 1.5 % (v/v) HFIP. We have 
previously shown that this concentration of HFIP induces AE aggregation over a time window of 
several minutes that can be easily followed in real-time using FSQ as the optical readout.[33-34] In the 
absence of 17E-HSD10, the addition of 1.5 % (v/v) HFIP to a non-aggregated solution of 1 PM AE555 
in 50 mM Tris-HCl buffer (pH 7.9) at qC under continuous agitation induced a decrease in 
fluorescence intensity of 60 ± 4 % over a 30-minute timescale (Figure 4A). When 1 PM AE555 was 
induced to aggregate under the same experimental conditions, but in the presence of the 17E-
HSD10 at AE555: 17E-HSD10 molar ratios of 2:1 and 1:1, the self-quenching efficiencies were 
measured to be 19 ± 4 % and 13 ± 3 %, respectively (Figure 4A). Importantly, no quenching was 
observed in a similar 30-minute time window when AE555 and 17E-HSD10 were incubated at a 1:1 
molar ratio in the absence of HFIP (Figure S3), confirming that under these conditions, 17E-HSD10 
interacts with AE during the HFIP-induced self-assembly process.  
   For comparative purposes, we have also explored the use of ThT fluorescent enhancement to 
monitor the formation of these globular structures and its inhibition by 17E-HSD10. Interestingly, we 
have found that the real-time injection of < 4% (v/v) HFIP to a buffered solution of 1.5 PM ThT (50 
mM Tris-HCl buffer, pH 7.9, at 4oC) induces a significant increase (~ 4-fold) in its fluorescence 
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emission over a 5-10 minute time period, even in the absence of amyloid (Figure 4B). ThT emission 
enhancement has been extensively used as a reporter of HFIP-induced aggregation[41,45] and the 
emissive behaviour of the ThT dye in different restricted media including E-sheet and non-E-sheet 
cavities such as cyclodextrin, polymer films and micelles has been discussed in detail.[45] In contrast, 
no detailed investigation of ThT emission in mixtures of water and polyfluorinated solvents, which 
are known to form microdroplets and solvent clusters, has been reported.[47] However, the 
formation of HFIP micro-droplets acting as adsorption platforms for bovine serum albumin has 
already been discussed using TEM[42] and micro-heterogeneities in HFIP-water mixtures have been 
studied in detail using NMR and small angle neutron scattering (SANS) experiments revealing a 
correlation in lengths ranging from 7 to 10 Å.[54] Interesting these lengths match the diameter (8-9 Å) 
of J-CD cavities which are known to promote the characteristic enhancement in ThT emission.[45] 
From NMR and SANS data it has been suggested that these micro-heterogeneities are maximized at 
HFIP concentrations of 30-35 % (v/v) and that the clusters organize with the trifluoromethyl (CF3) 
groups pointing inside the core and hydroxyl (OH) groups forming hydrogen bonds with the 
surrounding water molecules.[54] At lower concentrations of HFIP (< 5 % v/v) oligomers have been 
detected by mass spectrometry but their size and stoichiometry remains unknown.[54]  
   The influence of HFIP on the photophysical properties of the ThT dye in aqueous solution was 
further investigated by monitoring its absorption spectrum as a function of HFIP concentration. We 
observed a significant decrease in the absorption values with the addition of 1.5 % (v/v) and 4 % 
(v/v) concentration of HFIP (Figure S4), whilst higher concentrations (~ 30 %) reversed this behaviour 
and additionally shifted the absorption maximum (Figure S4). Similar features were found for the 
absorption (Figure S5A) and emission spectra (Figure S5B) when replacing HFIP by TFE, although for 
the latter the effect required to induce a similar change is less pronounced. Our data suggest that 
the observed variation in the photophysical properties of ThT might arise from an interaction with 
the droplet-water interface that alters its molecular-rotor properties or from local changes in the 
dielectric constant that are known to influence ThT emission[47] and they clearly indicate that care 
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should be taken when interpreting its use as a reporter of amyloid aggregation in mixtures of water 
and polyfluorinated solvents.  
  In view of the uncertainties associated with the use of ThT to monitor HFIP-induced aggregation 
and taking into account the spherical organization of the globular aggregates, we decided to employ 
dynamic light scattering (DLS) as an alternative method to contrast our FSQ results and determine 
how these HFIP-induced aggregates are affected by the presence of 17E-HSD10. In the absence of 
17E-HSD10, the values for the hydrodynamic radius (RH) are broadly distributed between 60 nm and 
400 nm (Table S2). These values are in good agreement with those previously reported by DLS and 
multi-angle light scattering (200-300 nm) for globule growth at similar HFIP concentrations.[41] Upon 
incubation with 17E-HSD10, a marked decrease in the RH was observed at both AE:17E-HSD10 molar 
ratios of 2:1 and 1:1, where values of 44.9-108.0 nm and 36-150 nm were observed respectively 
(Table S2), corresponding to a decrease in molecular mass close to an order of magnitude. We 
interpret this decrease in average RH as additional evidence for the inhibitory effect of 17E-HSD10 on 
globular aggregates. 
   Taken together, the FSQ and DLS data provide clear evidence for 17E-HSD10 inhibiting the 
formation of globular aggregates and suggests that the interaction of 17E-HSD10 with AE(1-42) must 
take place at a rate that competes with the relatively fast average aggregation rate reported for the 
globular aggregate (< 2 min-1).[34] It has been shown previously that freshly prepared HFIP-induced 
globules are highly unstable against dilution and evolve over time into more stable and still soluble 
fibrillar aggregates.[34,42] Based on this, we hypothesize that a potential pathway to explain the 
inhibitory action of 17E-HSD10 towards globular species may involve the interaction and 
sequestering of AE material that is in dynamic exchange with the globular structures. The concept of 
an equilibrium between globules and low-molecular weight AE structures is strongly supported by 
the evolution of these globules into more stable structures over time. Remarkably, the ability of 17E-
HSD10 to disrupt the formation of globular aggregates is significantly more pronounced than that 
reported for chaperone proteins including DB-crystallin[57] and the small heat shock protein 20 
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(Hsp20),[33] which constitute examples of the ďŽĚǇ ?Ɛ defense against protein misfolding.[33] For 
instance, wild-type Hsp20 does not show any ability to interfere with the formation of globular 
aggregates even at AE:Hsp20 molar ratios (1:2) higher than those employed here for 17E-HSD10.[33]   
 
17E-HSD10 does not inhibit amorphous plaque-like aggregate formation in acidic conditions 
   It has been established that AE peptides are found within the mitochondria of AD brains[11] and it 
has been suggested that soluble AE aggregates (monomeric and oligomeric structures) enter the 
mitochondria via the transporter outer membrane (TOM) machinery.[12] As a mitochondrial protein, 
we hypothesised that 17E-HSD10 is unlikely to interact with large plaque-like material usually found 
to aggregate in lysosome environments under slightly acidic conditions (pH 6); however, to date, no 
direct experimental evidence had been reported to confirm this. Therefore, we decided to take 
advantage of the robustness of FSQ-based methods over a wide pH range to test the potential 
interaction between 17E-HSD10 and plaque-like aggregates formed at similar AE555: 17E-HSD10 
molar ratios as those used to investigate the interaction with globules and fibrils. In the control 
experiment, a solution of 1 PM AE555 in 50 mM MES buffer (pH 6) at 37 oC induced a decrease in 
fluorescence intensity of 21.1 ± 0.5 % over a 50-minute timescale (Figure 5A). However, no 
significant inhibition was detected at AE555: 17E-HSD10 molar ratios of 2:1 and 1:1. Under such 
conditions, the degree of FSQ remained largely invariant, with quenching values of 21.1 ± 0.9 % and 
14.4 ± 0.7 %, respectively (Figure 5B, C). N-terminally labelled HiLyte Fluor 555 AE 42) quenching 
rates obtained under these conditions in the presence and absence of 17E-HSD10 are shown in 
Table S3 and the fluorescence spectra obtained at the different molar ratios are shown in Figure S6.  
   Although amyloid staining methods based on extrinsic probes, such as ThT, are known to suffer 
from a decrease in affinity as high as 30-fold when the pH decreases from pH 8.5 to pH 6,[40] they 
have been previously used to monitor aggregation at endosomal pH. For comparison with the FSQ 
data, we carried out an identical set of experiments using the emission of ThT as a probe. For 
unlabelled AE (1-42) in the absence of 17E-HSD10 we observed a 32.0 r 0.2 % enhancement of 
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fluorescence over a 50-minute time scale (Figure 5A). At AE (1-42): 17E-HSD10 molar ratios of 1:1 
and 2:1, the overall ThT enhancement remained largely invariant and emission enhancements of 
23.6 r 0.3 % and 22.8 r 0.2 % were observed, respectively (Figure 5B, C). The observation using ThT 
that 17E-HSD10 does not inhibit aggregation at pH 6 is therefore entirely consistent with our 
analysis using FSQ. 
 
Amyloid-induced inactivation of 17E-HSD10 enzymatic function 
   17E-HSD10 is the only human protein found to interact with AE in a yeast two-hybrid screening,[21] 
suggesting that AE-induced cytotoxicity takes place mostly through its interaction with 17E-
HSD10.[18,36,50] The current hypothesis suggests that HSD10 in complex with AE becomes 
dysfunctional and leads to an increased mitochondrial stress and ultimately loss of neuron 
viability.[50] The inhibitory effect of AE(1-42) on 17E-HSD10 binding to the NADH/NAD+ cofactor has 
already been confirmed using surface-plasmon resonance (SPR) and saturation transfer difference 
(STD) NMR experiments.[29] However, the precise morphological state of AE(1-42) that inactivates 
17E-HDS10 has not been established. Our FSQ data indicates that 17E-HDS10 interacts with fibrillar 
and globular amyloid structures but not with plaques; therefore, we decided to investigate the 
enzymatic activity of 17E-HDS10 under fibril- and globule-growing conditions.  
   Before assessing the influence of amyloid aggregation state on the function of 17E-HSD10, it was 
important to ascertain if the enzyme itself was active in the specific buffers required to promote 
these morphologies. For this, we employed an assay that monitors changes in NADH absorbance. 
During the conversion of substrate (acetoacetyl coenzymeA) to product, 17E-HSD10 uses NADH as a 
cofactor, converting it to NAD+. Thus, the loss of absorbance of NADH at 340 nm (as it is converted to 
NAD+) is a measure of 17E-HSD10 activity (Figure 6A). Specific activity values for 17E-HSD10 were 
calculated in Pmol min-1 mg-1 for this assay, and the background observed in the negative control 
(when no 17E-HSD10 is present in the reaction mixture) is minimal with values of around 0.2 Pmol 
min-1 mg-1, compared to positive control values of approximately 4 Pmol min-1 mg-1 for a reaction 
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mixture containing 5 Pg/ml 17E-HSD10 (Figure 6B). Under both oligomeric/ fibril like (50 mM Tris-
HCl buffer solution containing 150 mM NaCl) and globular aggregation buffer conditions (50 mM 
Tris-HCl (no NaCl), 1.5 % (v/v) HFIP) there was no change in specific 17E-HSD10 activity (Figure 6B). 
Under plaque-growing conditions (pH 6.0, 50 mM MES, 37°C) only a very slight decrease in 17E-
HSD10 activity (< 4 %) was observed (Figure 6B).   
   When the absorbance assay was repeated at conditions that induce the real-time aggregation of 
amyloid we observed a morphology-dependent response. At fibril-growing conditions, the level of 
enzymatic inhibition showed a dependence with the AE(1-42):17E-HSD10 molar ratio. At 1:1 and 2:1 
molar ratios, the enzymatic activity decreased by 3.4 ± 1.9 % and 20.2 ± 1.6 %, respectively (Figure 
6C). When we used experimental conditions that promote the formation of globular structures, we 
observed a very moderate decrease in the enzymatic activity (5.4 ± 1.7 %), even at the highest 5:1 
AE(1-42):17E-HSD10 molar ratio employed. Taken together, these data suggest that certain amyloid 
morphologies exhibit higher toxicity levels towards 17E-HSD10 function and confirm that, in a rich 
amyloid environment, the formation of AE(1-42) fibrils has a deleterious effect on 17E-HSD10 
activity.   
Discussion 
   A bar plot summarizing the relative variation in fluorescence self-quenching observed for the 
aggregation of 1 PM AE555 into globular, fibrils and amorphous plaque-like aggregates in the 
presence and absence of 17E-HSD10 is shown in Figure 7A and compared with the results from a 
ThT-based assay for fibrils and plaques in Figure 7B. Overall, both methods provided strong evidence 
for 17E-HSD10 preferentially interacting with certain amyloid morphologies. Specifically, 17E-HSD10 
demonstrated inhibitory potential towards globular and fibrillar structures formed at neutral 
conditions, but it displayed no effect on the aggregation mechanism of plaque structures formed in 
vitro at pH 6. A certain degree of preferential interaction of 17E-HSD10 with some amyloid 
aggregates could be anticipated based on the crystal structure of the 17E-HSD10/ AE(1-42) complex 
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that reveals the presence of a large cavity (~ 70 Å) that could easily accommodate fibrillar structures 
(40-60 Å), but not, for instance, plaque-like aggregates.[11]  
   The stoichiometry of the AE-17E-HSD10 complex has not yet been determined but it has been 
hypothesized that 17E-HSD10 does not interact with AE(1-42) monomers during surface plasmon 
resonance (SPR) and nuclear magnetic resonance (NMR) experiments.[11,29] Therefore, it is unlikely 
that physical and/or structural differences between the monomeric state of AE(1-42) at different pH 
can account for the observed discrimination between plaque-like structures formed at pH 6 and 
fibrils and globules formed at neutral conditions. Moreover, 17E-HSD10 at identical conditions as 
those used to generate amorphous plaque-like aggregates showed enzymatic levels comparable to 
neutral pH (Figure 6B), confirming that the numerous interactions the substrate forms with loops LF, 
LE and LD are conserved at slightly acidic conditions. In particular, the LD loop region which has been 
shown by mutagenesis studies and NMR analysis to be the 17E-HSD10 interface with AE,[29] should 
remain accessible for AE binding.   
   Since in all our in vitro assays, 17E-HSD10 is present in the aggregation mixture from the very early 
stages, we hypothesize that either differences in the structure of the aggregation intermediates or in 
the kinetics of the aggregation pathway between neutral and slightly acidic conditions may be 
responsible for the observed differences. This hypothesis is supported by experimental evidence 
suggesting that indeed both amyloid morphology and aggregation kinetics at pH 6, are remarkably 
different from those at neutral conditions.[39,60] Recent in vivo studies have also determined that 
intra-neuronal AE(1-42) aggregates faster in lysosomes and without a detectable lag phase, and this 
finding was justified in terms of the acidic environment bringing the peptide closer to its isoelectric 
point.[61] Using a combination of fluorescence methods and structural techniques, it has been shown 
that amyloid aggregation at pH 5.8 is characterized by the rapid formation (~ 10 seconds) of 
amorphous aggregates with sizes ranging from 50 to 500 nm.[40] Importantly, as determined by 
circular dichroism (CD), these aggregates do not contain D-helical or E-structure and they are unable 
to seed fibril formation.[40] It has also been demonstrated that the aggregates evolve into smaller 
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structures (30-80 nm) after 30 minutes which agrees well with the time window of the aggregation 
process observed in our FSQ and ThT experiments (Figure 5). The time scale of the initial growth 
phase is within our mixing time, so it is likely that with the time resolution of our assay, we are 
monitoring the disappearance of the initially formed aggregates as they slowly evolve into other 
morphologies. As reported by Gorman and coworkers,[39] these slow-forming morphologies also 
displayed very little, if any, E-structure. However, a lack of E-sheet structure at acidic pH cannot 
exclusively account for the observed lack of aggregation inhibition, as it has been shown that 17E-
HSD10 does not bind AE(25-35), which is known to exhibit a E-sheet conformation by CD and NMR 
studies.[63] 
   In contrast, the conformation of the N-terminal region, residues 17-20 of AE(1-20) that constitute 
the binding interface with 17E-HSD10,[11] is known to exhibit a random-coil/D-helix/E-sheet 
equilibrium that is highly dependent on pH conditions.[61,63,64] At pH 7-8, it has been demonstrated 
that residues 10-28, containing the putative 17E-HSD10 binding interface, are in equilibrium 
between random coil and D-helix conformations. In the region between pH 4-7, this equilibrium 
includes a further E-sheet conformation. Taken together, our data suggests that such pH-induced 
conformational re-arrangements of the N-terminal may be crucial to modulating the specific 
interaction of 17E-HSD10 with certain amyloid morphologies.  
   We further extended our analysis of the interaction between AE(1-42) and 17E-HSD10 to explore 
how the different aggregation conditions impact the enzymatic activity. Our results indicate that 
although 17E-HSD10 can efficiently inhibit the formation of fibrils and globules, rich amyloid 
conditions that promote the formation of fibrillar structures constitute the more toxic environment 
inducing a 20.2 % decrease in enzymatic function (Figure 6C). As previously discussed, the crystal 
structure of 17E-HSD10 bound to AE indicates the presence of a large solvent cavity involving the LD 
loop with estimated dimensions of 70 Å. These dimensions are relatively close to the diameter of 
amyloid fibrils (4-6 nm) but much smaller than the average diameter (~ 22 nm) measured by TEM 
and DLS for globular structures.[34,42] Therefore, it is possible that the higher enzymatic inhibition 
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observed under fibril-forming conditions is arising from the ability of these structures to drift and fit 
into this cavity and block the active site region, thus inactivating the enzyme.   
   Our data also provides evidence for an uncoupling between the determinants that influence the 
formation of AE/17E-HSD10 complexes and those that mediate suppression of enzymatic activity by 
amyloid fibrils at much higher AE concentrations. The observation that high AE(1-42): 17E-HSD10 
molar ratios of amyloid are required to have a significant impact on activity agrees well previous 
studies where the concentration of AE required for half-maximal inhibition was in the micromolar 
range (1-3 PM)  rather than the nanomolar range (~ 40 nM) required for efficient binding and most 
likely present at intracellular level.[18] The need for a rich amyloid environment to impair activity is 
also further supported by in vivo studies using SH-SY5Y human neuroblastoma cells that showed a 
decrease in the efficiency of 17E-HSD10 catalyzed estradiol to estrone conversion upon incubation 
with a high concentration of AE.[50] It has been suggested that the N-terminal domain of AE may be 
involved in the initial association to 17E-HSD10, and in a rich amyloid environment, the C-terminal 
portion is free to interact and recruit additional AE molecules resulting in a macromolecular complex 
that distorts the enzyme and alters its function.[18] Evaluating all this evidence together, we 
hypothesize that intracellular amyloid toxicity is not exclusively arising from the formation of 
AE/17E-HSD10 complexes but it is amplified by this secondary recruitment of amyloid molecules 
that may disrupt (for example) the quaternary organization of the enzyme, modify its substrate 
specificity or its localization and thus increase cell vulnerability. 
 
Conclusion 
   The biophysical characterization of the AE/17E-HSD10 interaction is pivotal for a full understanding 
of the interaction between AE accumulated inside nerve cells and intracellular proteins. 
Unfortunately, the exact details of the AE/17E-HSD10 interaction have remained elusive by X-ray 
crystallography and, as demonstrated here, ThT-based methods to monitor amyloid aggregation and 
its inhibition by 17E-HSD10 are not suitable at all experimental conditions. Consequently, the range 
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of amyloid morphologies capable of interacting with 17E-HSD10 has remained elusive. In the present 
study, we took advantage of the robustness of fluorescence self-quenching methods to monitor the 
inhibitory efficiency of 17E-HSD10 against a range of amyloid morphologies. Our results 
demonstrate preferential inhibition towards globular and fibril-like aggregates formed under neutral 
conditions by 17E-HSD10. The lack of inhibition towards amorphous plaque-like aggregates, 
generated at slightly acidic conditions, was discussed in terms of the known influence of pH on the 
conformational equilibrium of the N-terminal fragment of the AE peptide, which contains the 
putative AE/17E-HSD10 binding interface. From the range of morphologies that were found to 
interact with 17E-HSD10, inhibition of acetoacetyl-CoA reduction was only detected at fibril-forming 
conditions and when AE(1-42) was present at concentrations much higher than those required for 
efficient binding.  This work provides insights into the dependence of the AE/17E-HSD10 interaction 
with the morphology of amyloid aggregates and suggests that the determinants that mediate AE(1-
42) binding to 17E-HSD10 are different from those than influence the suppression of 17E-HSD10 
activity.   
 
Experimental 
All aqueous solutions were prepared with deionized water (Millipore, UK) and all chemicals 
purchased from Sigma Aldrich, UK unless stated otherwise.  
 
17E-HSD10 Purification 
Cell pellets of E. coli BL21-CodonPlus cells containing Histev-17E-HSD10 protein were re-suspended 
for 30 min, 4 °C, in lysis buffer (20 mM NaH2PO4, 30 mM imidazole, 500 mM NaCl, 10 % (v/v) 
glycerol, pH 7.5) with the addition of complete EDTA-free protease inhibitor tablets (Roche), 
lysozyme (1 mg/mL), DNase (20 Pg/mL) and Triton X-100 (0.1 % (v/v)). Cells were lysed by passage 
through a cell disruptor at 30 kPSI (Constant Systems Ltd) and the lysate was cleared by 
centrifugation (Sorvall Evolution RC, rotor S5-34 55-34 angle, 20500 rpm, 30 min, 4 °C). Cleared 
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lysate was filtered (0.44 Pm membrane; Whatman) then applied to a Ni-NTA (GE Healthcare) column 
pre-washed with lysis buffer and protein eluted with 300 mM imidazole buffer (20 mM NaH2PO4, 
300 mM imidazole, 500 mM NaCl, 10 % (v/v) glycerol, pH 7.5). Tobacco etch virus (TEV) protease was 
added to the protein at a mass-to-mass ratio of 1:10, to cleave the histidine tag and the protein was 
then dialysed into 20 mM Tris-HCl, 30 mM imidazole, 500 mM NaCl, 10% (v/v) glycerol, pH 7.5 
containing EDTA (1 mM) and DTT (1 mM) to aid solubility. Protein digestion and dialysis was carried 
out at 4 °C for 16 h.  
Complete digestion was firstly checked by SDS- PAGE, then fully digested protein was passed over a 
second Ni-column and the flow-through, containing 17E-HSD10 protein, was concentrated using a 
Vivaspin column (10 kDa MWCO, GE Healthcare) to ~ 7 mL before final purification using gel 
filtration to remove imidazole (Hi-Load 16/60 Superdex 75 prep grade column, GE Healthcare, flow 
rate 1.5 mL/min). Protein was eluted in gel filtration buffer (10 mM Tris-HCl, 150 mM NaCl, 10% 
glycerol, pH 7.5) and concentrated (Vivaspin column (10 kDa MWCO, GE Healthcare)) to 10 mg/mL. 
Aliquots (10 PL) were taken and flash frozen in liquid nitrogen before final storage at -80 °C. 
17E-HSD10 Activity Assay 
17E-HSD10 was diluted from frozen stock solution to a 0.2 mg/mL working stock in assay buffer 10 
mM Tris-HCl, 150 mM NaCl, 10 % (v/v) glycerol, pH 7.5 (at 30 °C). Acetoacetyl-CoA substrate 
(AcAcCoA) was prepared as a 4.8 mM stock in assay buffer, and nicotinamide adenine dinucleotide 
(NADH) was prepared as a 10 mM stock in assay buffer. Using a Nunc 96 well plate the enzyme 
activity assay was set up to give final assay concentrations as follows: 120 PM AcAcCoA, 250 PM 
NADH and 8 Pg/mL 17E-HSD10. In order to initiate the reaction 17E-HSD10 is added and the initial 
ƌĂƚĞŝƐƌĞĐŽƌĚĞĚŽǀĞƌƚŚĞĨŝƌƐƚ ? ?ƐƵƐŝŶŐƚŚĞ&>hKƐƚĂƌƉůĂƚĞƌĞĂĚĞƌ ?D'>ĂďƚĞĐŚ ?ƉĂƌĂŵĞƚĞƌƐʄA? ? ? ?
nM, T= 30 °C, 0.5 s orbital measuring intervals). Enzyme activity waƐĐĂůĐƵůĂƚĞĚƵƐŝŶŐ ?ɸA?  ? ? ? ?D-1 
cm-1 for NADH, where the NADH rate of consumption = AcAcCoA rate of reduction. Assays were 
performed by triplicate and the error was reported as ± SEM (standard error mean).   
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HiLyte Fluor 555 
Synthetic dye labelled AE1 W42 peptides incorporating HiLyte Fluor 555 were purchased from 
Anaspec Inc. (USA) and used with no additional purification, further details can be found in the 
supplementary information.  
Amyloid Monomer Preparation and Fluorescence Spectroscopy of AE(1-42) Aggregates 
The methods for amyloid monomer preparation and fluorescence spectroscopy of AE(1-42) 
aggregates can be found in the supplementary materials. 
Aggregation protocols 
Aggregation protocols for the three conditions investigated have been previously published [33,34,52] 
and details can be found in the supplementary materials. 
Dynamic Light Scattering 
Dynamic light scattering methods can be found in the supplementary materials. 
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Figure Legends 
Figure 1. Production, aggregation and accumulation of AE peptides within the brain is associated 
with neural dysfunction. AE peptides are formed within the cell membrane via cleavage of the 
amyloid precursor protein (APP) by E-secretase cleaving enzymes (BACEs). Soluble AE oligomers 
interact with cell-surface membranes and receptors, as well as intracellular components to lead to 
neuronal dysfunction. In particular, AE interactions with 17E-HSD10 in the mitochondria can lead to 
the inhibition of 17E-HSD10 activity which in turn leads to toxicity and mitochondrial dysfunction. AE 
can also self-assemble into pathogenic fibrils, plaques and other higher-order structures, displacing 
vital cellular components and leading to their malfunction. 
Figure 2. Principle of the fluorescence self-quenching (FSQ) assay to monitor the aggregation of the 
E-amyloid (AE) peptide. A) HiLyte Fluor 555 fluorescence is progressively quenched via FSQ as 
monomers aggregate. This may lead to the combination of partially quenched and completely 
quenched (non-emissive) states. The morphology shown is for illustrative purposes only and the 
schematic is not drawn to scale. B) Variation in the emission spectra of HiLyte Fluor 555 attached to 
the N-terminal of AE(1-42) as a function of aggregation time and C) representative fluorescence 
intensity profile during aggregation of 1 PM AE555 over a 30-minute time window. Oexc = 547 nm. 
Figure 3. Representative aggregation time courses obtained for 1 PM AE555 using FSQ (black circles) 
and for unlabelled AE(1-42) using ThT enhancement (grey squares) under fibril forming conditions in 
the presence of 17E-HSD10 at AE:17-E-HSD10 molar ratios of A) 1:0, B) 2:1 and C) 1:1. Solid lines 
represent the results from a fit to a monoexponential decay function using non-linear squares fitting. 
Solid lines in C) represent the fitting to a straight line. 
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Figure 4. A) Representative aggregation time courses obtained using FSQ for the HFIP-induced 
aggregation of AE555 in the presence of 17E-HSD10 at AE555:17E-HSD10 molar ratios of 1:0 (black, 
control), 2:1 (blue) and 1:1 (red) as a function of time at 4 oC after injection of 1.5 % (v/v) HFIP. The 
solid lines are fits to exponential decay functions. B) ThT fluorescence enhancement in the absence 
of AE(1-42) at the indicated concentrations of HFIP.  
Figure 5. Representative aggregation time courses obtained for 1 PM AE555 using FSQ (black circles) 
and for unlabelled AE(1-42) using ThT enhancement (grey squares) at pH 6 in the presence of 17E-
HSD10 at AE:17E-HSD10 molar ratios of A) 1:0, B) 2:1 and C) 1:1. Solid lines represent the results 
from a fit to a monoexponential decay function using non-linear squares fitting. 
Figure 6. Absorbance screening assay used to assess 17E-HSD10 enzyme activity. A) Conversion of 
substrate (Acetoacetyl coenzymeA) to product uses NADH as a cofactor, converting it to NAD+. The 
loss of absorbance of NADH at 340 nm (as it is converted to NAD+) is directly proportional to the rate 
of 17E-HSD10 activity. When no 17E-HSD10 is present (black line) there is no NADH consumption in 
comparison to when 17E-HSD10 is present in the assay (red line). Background absorbance (buffer 
only) is shown also shown (blue line). B) Enzymatic activity obtained for 17E-HSD10 (Pmol min-1 mg-
1) in the absence of amyloid at the different aggregation buffers used: (A) fibril-growing buffer: 10 
mM Tris-HCl pH 7.5, 150 mM NaCl, 10 % (v/v) glycerol; (B) pH6 induced aggregation buffer: 50 mM 
MES pH 6.0; (C) HFIP-induced aggregation buffer: 50 mM Tris-HCl pH 7.9, 1.5% HFIP (v/v). C) 
Percentage of 17E-HSD10 enzyme activity remaining in the presence of 1 PM freshly prepared AE(1-
42) under fibril (blue) and globule-growing (red) conditions at the indicated molar ratios of AE(1-42) 
and 17E-HSD10.  
Figure 7. Comparative bar plots summarizing the relative variation in fluorescence self-quenching A) 
and ThT enhancement B) observed for the aggregation of 1 PM AE555 and AE(1-42), respectively, into 
globules (red), fibrils (blue) and plaques (green) at AE: 17E-HSD10 molar ratios of 1:0 (control), 2:1 
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and 1:1.  Data are expressed as the mean ± SEM from A?3 separate experiments. ND indicates that no 
aggregation was detected.  
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17E-HSD10 interaction with AE amyloid: what type of amyloid? 17E-hydroxysteroid dehydrogenase 
type 10 is a mitochondrial enzyme known to interact with E Wamyloid (AE) aggregates and suppress 
AE-induced apoptosis in neurons, but the morphology of the amyloid aggregates predominantly 
inhibited by 17E-HSD10 remains unknown. A fluorescence self-quenching (FSQ) strategy was used to 
monitor the interaction in real time (left panel) and demonstrate that fibrils and globular aggregates, 
but not plaques, are specifically targeted by 17E-HSD10 (right panel). 
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